Funding
← Back to your selection

Frazier Life Sciences

Activity from announced rounds

Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$505M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series C+1

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
AirNexis Therapeutics

AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.

$200MSeries A
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed